| Product NDC: | 0006-3931 |
| Proprietary Name: | ZIOPTAN |
| Non Proprietary Name: | TAFLUPROST |
| Active Ingredient(s): | .0045 mg/.3mL & nbsp; TAFLUPROST |
| Administration Route(s): | OPHTHALMIC |
| Dosage Form(s): | SOLUTION |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 0006-3931 |
| Labeler Name: | Merck Sharp & Dohme Corp. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA202514 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20120210 |
| Package NDC: | 0006-3931-36 |
| Package Description: | 1 POUCH in 1 CARTON (0006-3931-36) > 10 AMPULE in 1 POUCH > .3 mL in 1 AMPULE |
| NDC Code | 0006-3931-36 |
| Proprietary Name | ZIOPTAN |
| Package Description | 1 POUCH in 1 CARTON (0006-3931-36) > 10 AMPULE in 1 POUCH > .3 mL in 1 AMPULE |
| Product NDC | 0006-3931 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | TAFLUPROST |
| Dosage Form Name | SOLUTION |
| Route Name | OPHTHALMIC |
| Start Marketing Date | 20120210 |
| Marketing Category Name | NDA |
| Labeler Name | Merck Sharp & Dohme Corp. |
| Substance Name | TAFLUPROST |
| Strength Number | .0045 |
| Strength Unit | mg/.3mL |
| Pharmaceutical Classes | Prostaglandin Analog [EPC],Prostaglandin Receptor Agonists [MoA],Increased Prostaglandin Activity [PE],Prostaglandins [Chemical/Ingredient] |